Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers

Biopharmaceutics & Drug Disposition
Randall StoltzA Macciocchi

Abstract

Palonosetron (Aloxi(R), Onicit(R)) is a potent, single stereoisomeric 5-HT(3) receptor antagonist developed to prevent chemotherapy-induced nausea and vomiting. The pharmacokinetics and metabolic disposition of a single intravenous [(14)C]-palonosetron (10 microg/kg, 0.8 microCi/kg) bolus dose were evaluated in six healthy volunteers (three males, three females) using serial blood, plasma, urine and fecal samples obtained over 10 days. The safety, tolerability and cardiac effects were assessed. Radiolabeled metabolic characterization revealed that unchanged palonosetron accounted for 71.9% of the total radioactivity in plasma over 96 h, with an extensive distribution volume (8.34 l/kg) and mean plasma elimination half-life of 37 h. Approximately 83% of the dose was recovered in urine ( approximately 40% as unchanged drug, with 50% metabolized; M9 and M4 were the major metabolites) and 3.4% in feces. Hydrolysis of urine samples suggests that the metabolites are not beta-glucuronide or sulfate conjugates of the parent drug or metabolites. The blood to plasma concentration ratio of the total radioactivity was 1.2, on average, indicating little selective partitioning in erythrocytes. Palonosetron was generally well tolerated; heada...Continue Reading

References

Jan 1, 1991·Drug Design and Delivery·M B Tyers
Jun 12, 1990·European Journal of Pharmacology·I van WijngaardenW Soudijn
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C M LindleyS M Fields

❮ Previous
Next ❯

Citations

Jun 30, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MaemondoUNKNOWN PALO Japanese Cooperative Study Group
Feb 21, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Y F LiJ J Kavanagh
May 14, 2009·Therapeutics and Clinical Risk Management·Neil A Muchatuta, Michael J Paech
Oct 27, 2009·Drugs·Lily P H Yang, Lesley J Scott
Jun 18, 2011·Bioanalysis·Yuanyuan WangNing Ou
Mar 26, 2014·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yong HuangJi-zhou Wu
Feb 6, 2010·Expert Review of Anticancer Therapy·Christina Ruhlmann, Jørn Herrstedt
Aug 30, 2013·Expert Review of Anticancer Therapy·Sherry Mori-Vogt, Marlo Blazer
Aug 23, 2006·Expert Opinion on Drug Metabolism & Toxicology·Giuseppe ToniniDaniele Santini
May 19, 2005·Current Medical Research and Opinion·Ajit K ShahMichael T Cullen
Jan 21, 2009·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Paulo PaixãoJosé A G Morais
Feb 19, 2013·Expert Opinion on Pharmacotherapy·Alessandra Fabi, Paola Malaguti
Mar 14, 2014·Korean journal of anesthesiology·Han-Bom Ryu, Su-Jin Kim
Apr 13, 2019·Journal of Anesthesia·Seongheon LeeSeongwook Jeong
Aug 14, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Galina KurtevaAlberto Bernareggi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.